Duke Studies Find Little Difference In Outcomes Between Bypass Surgery And Angioplasty For Diabetics

November 13, 1996

NEW ORLEANS -- In contrast to the findings of a recent, highly publicized clinical trial and subsequent federal recommendation, two Duke University Medical Center studies suggest that diabetics with severe coronary artery disease do equally well if they receive either angioplasty or coronary artery bypass surgery.

While diabetics with multi-vessel disease tend to have slightly worse outcomes with both treatments when compared with non-diabetics with similar disease, the Duke researchers recommend that cardiologists not use diabetes as the main factor when considering which procedure is best for their patients.

The Duke studies were prepared for presentation Tuesday (Nov. 12) at the annual scientific meeting of the American Heart Association.

In July, investigators for a multi-center trial called BARI for Bypass Angioplasty Revascularization Investigation reported in the New England Journal of Medicine that the five-year survival for diabetics treated with bypass surgery was 80.6 percent, compared to 65.5 percent for diabetics treated with angioplasty. Shortly before the overall BARI results were published, the National Heart Lung Blood Institute recommended that diabetics with multi-vessel disease be treated with bypass surgery.

After the BARI results were published, Duke researchers conducted their own retrospective studies to see if the BARI results could be substantiated. While they acknowledge that their studies are retrospective, the researchers say the Duke studies provide more data that can be used in further discussion of the issue.

The studies were supported by, and drew upon the expertise of, the Duke Clinical Research Institute, which has been collecting and analyzing patient data relating to heart disease since 1969.

"Our long-term data show that a history of diabetes holds a similar risk for both angioplasty and bypass patients," said Dr. Greg Barsness, Duke cardiology fellow. "Rather than using diabetes to determine the revascularization choice, other factors should be considered, such as disease severity and technical considerations."

Barsness's study followed 3,220 patients (769 of whom were diabetic) who received either bypass or angioplasty at Duke between 1984 and 1990. After five years (the same follow-up for the BARI trial), 74.3 percent of the diabetics (vs. 86.3 percent for non-diabetics) who received bypass were alive, while 76.4 percent of diabetics (vs. 88.3 percent of non-diabetics) receiving angioplasty were alive.

"After adjusting for such factors as age, gender and characteristics of their heart disease, we found that diabetics receiving either angioplasty or bypass had lower survival than non-diabetics receiving these interventions," Barsness said. "However, in contrast to the results seen in the BARI trial, the decrease in survival was similar among both angioplasty- and bypass-treated diabetics."

For the second study, Dr. David Anderson, Duke cardiology fellow, pooled data from seven recent multi-center trials involving 6,338 patients who underwent angioplasty, 1,230 of whom were diabetics. Patients were followed for nine months after their procedures.

"At least for the short term, our study suggests that factors other than diabetes are more predictive of major adverse events after angioplasty," Anderson said. "Statistical analysis showed that while diabetics had slightly more revascularization during a nine-month follow-up period due to higher restenosis (where the artery closes again), other outcomes (death and heart attack) are best predicted by the number of diseased vessels feeding the heart, prior history of heart attack, and the degree of vessel blockage before the procedure."

Physicians still do not understand why diabetics tend to do worse than non-diabetics. While researchers have demonstrated that "tight" control of a diabetic's glucose levels significantly delays the disease's destructive effects on tiny blood vessels -- such as those in the eyes, extremities and kidneys -- they still do not know how the disease effects the body's larger blood vessels, like those supplying oxygen-rich blood to the heart.
-end-


Duke University

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.